Silence Therapeutics Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
88
- Stock Symbol
-
SLNCF
- Investments
-
2
- Share Price
-
$6.53
- (As of Thursday Closing)
Silence Therapeutics General Information
Description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact Information
Website
www.silence-therapeutics.comCorporate Office
- 12 Hammersmith Grove
- London W6 7AP
- England, United Kingdom
Corporate Office
- 12 Hammersmith Grove
- London W6 7AP
- England, United Kingdom
Silence Therapeutics Stock Performance
As of 12-Nov-2026, Silence Therapeutics’s stock price is $6.53. Its current market cap is $1.22B with 187M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.53 | $6.36 | $1.06 - $6.53 | $1.22B | 187M | 26.4K | -$0.35 |
Silence Therapeutics Financials Summary
As of 30-Sep-2026, Silence Therapeutics has a trailing 12-month revenue of $456K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 673,907 | 181,394 | 199,388 | 102,642 |
| Revenue | 456 | 559 | 43,258 | 31,643 |
| EBITDA | (91,526) | (48,343) | (54,454) | |
| Net Income | (51,421) | (88,612) | (45,309) | (54,228) |
| Total Assets | 281,498 | 131,442 | 202,635 | 119,448 |
| Total Debt | 87 | 160 | 117 | 346 |
Silence Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Silence Therapeutics Comparisons
Industry
Financing
Details
Silence Therapeutics Competitors (82)
One of Silence Therapeutics’s 82 competitors is Nanoviricides, a Corporation company based in Shelton, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nanoviricides | Corporation | Shelton, CT | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| BioCryst Pharmaceuticals | Corporation | Durham, NC | ||||
| Novavax | Corporation | Gaithersburg, MD |
Silence Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Silence Therapeutics Patents
Silence Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2011009082-A2 | Compositions comprising human rhbdf1-modulating nucleic acids and methods of use | Inactive | 17-Jul-2009 | ||
| WO-2011009082-A3 | Compositions comprising human rhbdf1-modulating nucleic acids and methods of use | Inactive | 17-Jul-2009 | ||
| WO-2011005980-A1 | Novel heterobifunctional polyethylene glycol reagents, their preparation and uses thereof | Inactive | 09-Jul-2009 | ||
| EP-2285959-A2 | Compositions comprising cmyc sirna and methods of use thereof | Inactive | 11-Jun-2008 | ||
| US-20110190375-A1 | Compositions comprising cmyc sirna and methods of use thereof | Inactive | 11-Jun-2008 | C12N15/1135 |
Silence Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Silence Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Silence Therapeutics Investments & Acquisitions (2)
Silence Therapeutics’s most recent deal was a PIPE with Arrowhead Pharmaceuticals for . The deal was made on 09-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 09-Jan-2017 | PIPE | Biotechnology | ||
| Intradigm | 05-Jan-2010 | Merger/Acquisition | Biotechnology |
Silence Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Silence Therapeutics Exits (1)
Silence Therapeutics’s most recent exit was on 09-Jan-2017 from Arrowhead Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 09-Jan-2017 | Completed |
|
Silence Therapeutics FAQs
-
When was Silence Therapeutics founded?
Silence Therapeutics was founded in 1994.
-
Where is Silence Therapeutics headquartered?
Silence Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Silence Therapeutics?
Silence Therapeutics has 88 total employees.
-
What industry is Silence Therapeutics in?
Silence Therapeutics’s primary industry is Biotechnology.
-
Is Silence Therapeutics a private or public company?
Silence Therapeutics is a Public company.
-
What is Silence Therapeutics’s stock symbol?
The ticker symbol for Silence Therapeutics is SLNCF.
-
What is the current stock price of Silence Therapeutics?
As of 12-Nov-2026 the stock price of Silence Therapeutics is $6.53.
-
What is the current market cap of Silence Therapeutics?
The current market capitalization of Silence Therapeutics is $1.22B.
-
What is Silence Therapeutics’s current revenue?
The trailing twelve month revenue for Silence Therapeutics is $456K.
-
Who are Silence Therapeutics’s competitors?
Nanoviricides, Alnylam Pharmaceuticals, Amunix Pharmaceuticals, BioCryst Pharmaceuticals, and Novavax are some of the 82 competitors of Silence Therapeutics.
-
What is Silence Therapeutics’s annual earnings per share (EPS)?
Silence Therapeutics’s EPS for 12 months was -$0.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
